Study: Diabetes Drug May Cut Risk of Alzheimer’s and Parkinson’s …
网页22 小时之前 · A study indicates that diabetes drugs called SGLT2 inhibitors may reduce the risk of dementia and Parkinson’s disease by up to 30%. SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, according to a large study.Results showed a 20% to 30% lower risk for these conditions, though further research is needed for long ...
SGLT2 Inhibitors Cut Kidney Risks Across CKD, Heart Failure, …
网页6 天之前 · SGLT2 inhibitors reduce the risk for adverse kidney outcomes across most high-risk populations with CKD, heart failure, and/or type 2 diabetes. Sodium glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk for adverse kidney outcomes across patient groups with different combinations of chronic kidney disease (CKD), type 2 …
SGLT2 inhibitor empagliflozin is shown to be safe and effective for ...
网页2024年9月2日 · The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction...
SGLT-2 inhibitors may reduce dementia risk - Diabetes
网页2024年9月14日 · Semaglutide: A Complete Guide. They found that taking SGLT-2 inhibitors was linked to a 35% lower risk of developing dementia in comparison to those on DPP-4 inhibitors. Another key finding was that people who had been on SGLT-2 inhibitors for longer than two years saw the biggest reduction in risk. The findings prompted the authors to …
FDA Update: Sotagliflozin Approved For Broad HF Treatment
网页2023年6月5日 · The U.S. Food and Drug Administration (FDA) on May 26 approved a new drug application submitted by Lexicon Pharmaceuticals, Inc. for sotagliflozin (Inpefa), the first dual SGLT1 and SGLT2 inhibitor for the treatment of heart failure (HF), including HF with preserved ejection fraction and HF with reduced ejection fraction.
SGLT2 Inhibitors Reduce Cardiovascular Risks Independent of GLP …
网页2024年6月20日 · Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular and kidney outcomes in patients with type 2 diabetes with or without concomitant use of glucagon-like peptide-1...
FDA approves first SGLT1/SGLT2 inhibitor for heart failure
网页2023年6月29日 · Patients now have an even better chance at survival with the recent FDA approval of Inpefa, the brand name of the drug sotagliflozin. It is the first sodium glucose cotransporter (SGLT) inhibitor that addresses glucose reabsorption in both the kidneys and the small intestine.
KDIGO provided recommendations on SGLT2 inhibitors and …
网页2023年5月12日 · Sodium-glucose cotransporter-2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs) are now recommended for more patients with chronic kidney disease (CKD), but data are needed on their cost-effectiveness, an ACP Journal Club commentary said.
SGLT2 inhibitors in CKD and HFpEF: two new large trials and two …
网页2023年2月1日 · Results from two new trials and two new meta-analyses conclusively demonstrate the cardio-protective and kidney-protective effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors across the breadth of heart failure and chronic kidney disease populations studied, with absolute benefits convincingly outweighing the …
Applications of SGLT2 inhibitors beyond glycaemic control
网页2024年4月26日 · SGLT2 inhibitors reduce the risk of cardiovascular death and heart failure hospitalization among people with type 2 diabetes mellitus and have beneficial effects on key heart failure outcomes...